Jasper Therapeutics Inc (JSPR) concluded trading on Wednesday at a closing price of $6.99, with 6.56 million shares of worth about $45.88 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -64.82% during that period and on January 08, 2025 the price saw a loss of about -60.53%. Currently the company’s common shares owned by public are about 15.00M shares, out of which, 11.24M shares are available for trading.
Stock saw a price change of -67.31% in past 5 days and over the past one month there was a price change of -68.91%. Year-to-date (YTD), JSPR shares are showing a performance of -67.31% which decreased to -0.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.61 but also hit the highest price of $31.01 during that period. The average intraday trading volume for Jasper Therapeutics Inc shares is 281.61K. The stock is currently trading -65.96% below its 20-day simple moving average (SMA20), while that difference is down -67.72% for SMA50 and it goes to -67.62% lower than SMA200.
Jasper Therapeutics Inc (NASDAQ: JSPR) currently have 15.00M outstanding shares and institutions hold larger chunk of about 76.00% of that.
The stock has a current market capitalization of $104.86M and its 3Y-monthly beta is at 2.19. It has posted earnings per share of -$4.75 in the same period. It has Quick Ratio of 7.61 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for JSPR, volatility over the week remained 20.26% while standing at 10.56% over the month.
Stock’s fiscal year EPS is expected to rise by 27.23% while it is estimated to decrease by -1.62% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BMO Capital Markets on December 06, 2024 offering an Outperform rating for the stock and assigned a target price of $63 to it. Coverage by JMP Securities stated Jasper Therapeutics Inc (JSPR) stock as a Mkt outperform in their note to investors on September 09, 2024, suggesting a price target of $70 for the stock. On July 08, 2024, BTIG Research Initiated their recommendations, while on June 27, 2024, Stifel Initiated their ratings for the stock with a price target of $86. Stock get a Buy rating from H.C. Wainwright on May 06, 2024.
